Bayer’s Kerendia (finerenone) reduced the risk of cardiovascular and kidney disease events in patients with type 2 diabetes and chronic kidney disease, being especially effective in those with atherosclerotic cardiovascular disease (ASCVD).
Source: Drug Industry Daily